Tuberculosis remains one of the most consequential but underappreciated threats to global longevity, and this sweeping analysis arrives at a moment when funding cuts could reverse decades of painstaking progress. Understanding exactly where the burden sits — by country, HIV status, and drug-resistance profile — is foundational for anyone tracking infectious disease contributions to premature mortality and lost healthspan.
Drawing on the Global Burden of Disease 2023 dataset, researchers mapped TB incidence, prevalence, mortality, and disability-adjusted life-years (DALYs) across 204 countries and territories from 1990 through 2023. The analysis stratified outcomes by HIV co-infection and multidrug-resistant TB (MDR-TB) status using population attributable fraction modeling, and separately quantified how modifiable risk factors — alcohol use, smoking, and elevated fasting plasma glucose — contribute to overall TB burden. The methodology integrated vital registration records, surveillance data, verbal autopsies, and minimally invasive tissue sampling into an ensemble cause-of-death modeling framework alongside DisMod-MR 2.1 for morbidity estimation. Progress toward the WHO End TB Strategy targets — a 95% reduction in TB deaths and 90% reduction in incidence by 2035 relative to 2015 — was explicitly benchmarked.
This is arguably the most methodologically comprehensive TB burden assessment published to date, and its timing is critical. The WHO's 2035 targets were already considered ambitious before recent contractions in global health financing; this analysis provides the clearest pre-disruption baseline against which future setbacks can be measured. The HIV-TB co-infection stratification is particularly important because these populations carry disproportionate mortality risk and require integrated care pathways that are among the first casualties of funding shortfalls. The MDR-TB sub-analysis matters for longevity researchers because drug-resistant strains substantially extend treatment duration, increase disability burden, and erode treatment success rates. Key limitations include the inherent uncertainty in modeling TB burden in countries with weak vital registration infrastructure, and the cross-sectional GBD framework cannot establish causality for risk factor contributions. Nonetheless, for health-conscious adults and policy-adjacent readers, this study reframes TB not as a solved problem but as a resurgent threat with measurable, modifiable drivers.